Life Science Investing ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer Annual Meeting 03 October
Life Science Investing ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer 12 September
Life Science Investing ALX Oncology to Participate in Upcoming Investor Conferences in September 29 August
